Gain Therapeutics, Inc. (GANX)
After hours:
| Previous close | 3.0300 |
| Open | 3.0100 |
| Bid | 2.9500 x 100 |
| Ask | 3.0900 x 100 |
| Day's range | 2.8901 - 3.0300 |
| 52-week range | 2.0000 - 5.6500 |
| Volume | |
| Avg. volume | 160,412 |
| Market cap | 48.659M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Insider Monkey
Insiders are Piling into These 10 Healthcare Stocks in 2024
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]
- Zacks
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Gain Therapeutics (GANX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
